We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NIH Launches Trial of Remdesivir With Merck’s Rebif for COVID-19
NIH Launches Trial of Remdesivir With Merck’s Rebif for COVID-19
The NIH’s National Institutes of Allergy and Infectious Diseases (NIAID) has launched a phase 3 trial of Gilead Sciences’ remdesivir with Merck’s anti-inflammatory drug Rebif (interferon-beta-1a) for the treatment of hospitalized COVID-19 patients.